BR112021022635A2 - Formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol, um inibidor de shp2 - Google Patents

Formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol, um inibidor de shp2

Info

Publication number
BR112021022635A2
BR112021022635A2 BR112021022635A BR112021022635A BR112021022635A2 BR 112021022635 A2 BR112021022635 A2 BR 112021022635A2 BR 112021022635 A BR112021022635 A BR 112021022635A BR 112021022635 A BR112021022635 A BR 112021022635A BR 112021022635 A2 BR112021022635 A2 BR 112021022635A2
Authority
BR
Brazil
Prior art keywords
amino
methylpyrazin
decan
azaspiro
chloropyridin
Prior art date
Application number
BR112021022635A
Other languages
English (en)
Inventor
Shaoling Li
G Ballmer Steven
Original Assignee
Revolution Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revolution Medicines Inc filed Critical Revolution Medicines Inc
Publication of BR112021022635A2 publication Critical patent/BR112021022635A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil]-3-[(3s,4s)-4-amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5-metilpirazin-2-il}metanol, um inibidor de shp2. a presente invenção refere-se às formas sólidas cristalinas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol ou sal farmaceuticamente aceitável da mesma, ao processo de preparação das formas, e composições farmacêuticas e métodos de uso das mesmas.
BR112021022635A 2019-06-07 2020-06-04 Formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol, um inibidor de shp2 BR112021022635A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962858837P 2019-06-07 2019-06-07
PCT/US2020/036137 WO2020247643A1 (en) 2019-06-07 2020-06-04 Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor

Publications (1)

Publication Number Publication Date
BR112021022635A2 true BR112021022635A2 (pt) 2022-01-04

Family

ID=71787182

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022635A BR112021022635A2 (pt) 2019-06-07 2020-06-04 Formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol, um inibidor de shp2

Country Status (14)

Country Link
US (2) US11220501B2 (pt)
EP (1) EP3980128A1 (pt)
JP (1) JP2022534788A (pt)
KR (1) KR20220019017A (pt)
CN (2) CN114190090A (pt)
AU (1) AU2020288631A1 (pt)
BR (1) BR112021022635A2 (pt)
CA (1) CA3142430A1 (pt)
IL (1) IL288568A (pt)
MA (1) MA56113A (pt)
MX (1) MX2021014855A (pt)
SG (1) SG11202112461QA (pt)
TW (1) TW202112785A (pt)
WO (1) WO2020247643A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019051084A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER
CN114190090A (zh) 2019-06-07 2022-03-15 锐新医药公司 Shp2抑制剂{6-[(2-氨基-3-氯吡啶-4-基)硫烷基]-3-[(3s,4s)-4-氨基-3-甲基-2-氧杂-8-氮杂螺[4.5]癸烷-8-基]-5-甲基吡嗪-2-基}甲醇的固体形式
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
KR20240055778A (ko) 2021-09-01 2024-04-29 노파르티스 아게 Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
SG11201900157RA (en) 2016-07-12 2019-02-27 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
WO2019051084A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER
CN112203689A (zh) 2018-04-10 2021-01-08 锐新医药公司 治疗癌症的shp2抑制剂组合物和方法
CN114190090A (zh) 2019-06-07 2022-03-15 锐新医药公司 Shp2抑制剂{6-[(2-氨基-3-氯吡啶-4-基)硫烷基]-3-[(3s,4s)-4-氨基-3-甲基-2-氧杂-8-氮杂螺[4.5]癸烷-8-基]-5-甲基吡嗪-2-基}甲醇的固体形式

Also Published As

Publication number Publication date
KR20220019017A (ko) 2022-02-15
JP2022534788A (ja) 2022-08-03
WO2020247643A1 (en) 2020-12-10
US20210253574A1 (en) 2021-08-19
CN114190090A (zh) 2022-03-15
CA3142430A1 (en) 2020-12-10
IL288568A (en) 2022-02-01
US20220298159A1 (en) 2022-09-22
AU2020288631A1 (en) 2021-12-09
MA56113A (fr) 2022-04-13
TW202112785A (zh) 2021-04-01
SG11202112461QA (en) 2021-12-30
CN115141205A (zh) 2022-10-04
US11220501B2 (en) 2022-01-11
EP3980128A1 (en) 2022-04-13
MX2021014855A (es) 2022-01-18

Similar Documents

Publication Publication Date Title
BR112021022635A2 (pt) Formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol, um inibidor de shp2
CO2021008817A2 (es) Compuesto agonista de receptor thrβ y método de preparación y uso del mismo
CA3057882A1 (en) Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein
ECSP20013248A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
BR112022008375A2 (pt) Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste
BR112022012641A2 (pt) Compostos tricíclicos substituídos
BR112022004424A2 (pt) Pró-fármacos antivirais e formulações dos mesmos
BR112012003578A8 (pt) Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal
BRPI0607796A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
BR112014013974A8 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
BR112021011325A2 (pt) Derivados de rapamicina
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
AU2018274378A1 (en) Compound used as autophagy regulator, and preparation method therefor and uses thereof
WO2018201167A3 (en) Propionic acid derivatives and methods of use thereof
BR112021018578A2 (pt) Compostos de heterociclil(fenil)metanol úteis no tratamento de hiperglicemia
BR112021020297A2 (pt) Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune
CL2023001894A1 (es) Análogos de rifamicina y conjugados de fármaco-anticuerpo de los mismos
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
WO2019207257A8 (fr) Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
BRPI0607701A2 (pt) composto ou um sal, éster, solvato, estereoisÈmero, tautÈmero ou pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de uma quantidade antibacterialmente eficaz de um composto junto com um veìculo farmaceuticamente aceitável, e, método de preparação de um composto
BR112021023927A2 (pt) Composto, e, composição farmacêutica
BR112022005182A2 (pt) Composto de amida heterocíclico, sal farmaceuticamente aceitável do mesmo, e método de preparação do mesmo e uso do mesmo